Teglicar chloride
Teglicar chloride (ST1326 chloride) is an orally active, reversible, mixed-type, selective inhibitor of hepatic carnitine palmitoyltransferase I (L-CPT I), with an IC50 of 1.1 μM against rat L-CPT I. Teglicar chloride reduces serum glucose levels. Teglicar chloride exhibits antiketotic activity in normal fasted rats. Teglicar chloride can be used in research related to type 2 diabetes and ketoacidosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 908566-80-3
- Formel: C22H46ClN3O3
- Molecular Weight:436.07
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
CPT-1 |
L-CPT I 1.1 μM (IC50) |
Teglicar (0-3 mM; 1 min) chloride potently and selectively inhibits liver isoform CPT I (L-CPT I) from rat liver mitochondria with an IC50 of 1.1 μM, and shows 39.4-fold lower potency against heart isoform CPT I (M-CPT I) from rat heart mitochondria with an IC50 of 43.4 μM[1].
Teglicar (up to 50 μM; 48 h) chloride shows no cytotoxicity in rat hepatocytes at concentrations up to 50 μM after 48 h of incubation[1].
Teglicar (0.5-1.0 μM) chloride acts as a reversible, mixed inhibitor of L-CPT I expressed in Pichia pastoris with respect to palmitoyl-CoA, exhibiting an apparent Ki of 0.36 ± 0.04 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Teglicar (10-40 mg/kg; p.o.) chloride produces a dose-dependent reduction in serum β-hydroxybutyrate levels in 24-hour fasted male Sprague Dawley rats, with an ED50 of 14.5 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/KsJ-db/db (male, 8 weeks old)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; twice daily; 45 days
-
Result:Reduced serum glucose levels by 25% (from 673.9 ± 44.09 mg/dL to 506.6 ± 59.12 mg/dL).
Reduced serum fructosamine levels by 30% (from 4.80 ± 0.17 mmol/L to 3.36 ± 0.30 mmol/L).
Reduced liver glycogen by 25%.
Increased liver triglyceride content by 38%.
Increased serum free fatty acid levels by 20%.
Caused no significant changes in serum insulin, leptin, triglyceride, urea, alanine aminotransferase, or cholesterol levels.
Caused no effects on heart weight or heart triglyceride content.
Chemical Information
-
CAS. Nr. 908566-80-3
-
Molecular Weight 436.07
-
Formel C22H46ClN3O3
-
SMILES
CCCCCCCCCCCCCCNC(N[C@H](CC(O)=O)C[N+](C)(C)C)=O.[Cl-]
-
Synonyms
ST1326 chloride
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Teglicar chloride Related Classifications
HY-182248 Related Classifications
Powered by Bioz
- Teglicar
- 908566-80-3
- ST1326
- ST 1326
- ST-1326
- Carnitine Palmitoyltransferase (CPT)
- Acyltransferase
- ketoacidosis
- Sprague Dawley rats
- liver carnitine palmitoyltransferase I
- C57BL/KsJ-db/db mice
- type ii diabetes mellitus
- L-CPT I
- rat hepatocytes
- Pichia pastoris
- rat liver mitochondria
- rat heart mitochondria
- Inhibitor
- inhibitor
- inhibit